Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 74

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1
Chunk 74
---
 as contemplated elsewhere in this Annual Report on Form 10-K. 

If we fail to address the risks and difficulties that we face, including those described elsewhere in this “Risk Factors” section, our business, financial condition and results of operations could be adversely affected. We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by growing companies with limited operating histories in rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations and our business, financial condition and results of operations could be adversely affected. 

We may need to raise additional capital to fund our existing operations, develop our Platform, commercialize new products or expand our operations. 

We may need to raise additional capital in the future to expand our business, meet existing obligations, pursue acquisitions or strategic investments, or take advantage of financing opportunities or for other reasons, including to: 

•increase our sales and marketing efforts to drive market adoption of our current products and services, and address competitive developments; 

57

•fund development and marketing efforts of our products under development or any other future products we may develop; 

•acquire, license or invest in technologies; 

•acquire or invest in complementary businesses or assets; and 

•finance capital expenditures and general and administrative expenses. 

Our present and future funding requirements will depend on many factors, including: 

•our ability to achieve revenue growth and favorable gross profits; 

•our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial payers and government payers; 

•the cost of expanding our laboratory operations and product offerings, including our sales and marketing efforts; 

•our rate of progress in, and costs of our sales and marketing activities associated with, establishing adoption of and reimbursement for our current products, including our diagnostic tests and our data analytics products; 

•the rate at which we choose to advance, rate of progress in, and costs of our research and development activities associated with, products in development; 

•the effect of competing technological and market developments; 

•costs related to our international expansion; and 

•the potential costs of and delays in product development as a result of any existing or new regulatory oversight applicable to our products. 

We have no committed sources of capital. We may seek to sell equity or convertible securities, enter into a credit facility or another form of third